Your browser doesn't support javascript.
loading
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing.
Kaertner, L S; Steinborn, M B; Kettner, H; Spriggs, M J; Roseman, L; Buchborn, T; Balaet, M; Timmermann, C; Erritzoe, D; Carhart-Harris, R L.
Afiliación
  • Kaertner LS; Centre for Psychedelic Research, Division of Psychiatry, Imperial College London, London, UK. laura.kartner17@imperial.ac.uk.
  • Steinborn MB; Departmant of Psychology, Julius-Maximilans-University Würzburg, Würzburg, Germany.
  • Kettner H; Centre for Psychedelic Research, Division of Psychiatry, Imperial College London, London, UK.
  • Spriggs MJ; Centre for Psychedelic Research, Division of Psychiatry, Imperial College London, London, UK.
  • Roseman L; Centre for Psychedelic Research, Division of Psychiatry, Imperial College London, London, UK.
  • Buchborn T; Centre for Psychedelic Research, Division of Psychiatry, Imperial College London, London, UK.
  • Balaet M; Computational, Cognitive and Clinical Neuroimaging Laboratory, Imperial College London, London, UK.
  • Timmermann C; Centre for Psychedelic Research, Division of Psychiatry, Imperial College London, London, UK.
  • Erritzoe D; Centre for Psychedelic Research, Division of Psychiatry, Imperial College London, London, UK.
  • Carhart-Harris RL; Centre for Psychedelic Research, Division of Psychiatry, Imperial College London, London, UK.
Sci Rep ; 11(1): 1941, 2021 01 21.
Article en En | MEDLINE | ID: mdl-33479342
ABSTRACT
Psychedelic microdosing describes the ingestion of near-threshold perceptible doses of classic psychedelic substances. Anecdotal reports and observational studies suggest that microdosing may promote positive mood and well-being, but recent placebo-controlled studies failed to find compelling evidence for this. The present study collected web-based mental health and related data using a prospective (before, during and after) design. Individuals planning a weekly microdosing regimen completed surveys at strategic timepoints, spanning a core four-week test period. Eighty-one participants completed the primary study endpoint. Results revealed increased self-reported psychological well-being, emotional stability and reductions in state anxiety and depressive symptoms at the four-week primary endpoint, plus increases in psychological resilience, social connectedness, agreeableness, nature relatedness and aspects of psychological flexibility. However, positive expectancy scores at baseline predicted subsequent improvements in well-being, suggestive of a significant placebo response. This study highlights a role for positive expectancy in predicting positive outcomes following psychedelic microdosing and cautions against zealous inferences on its putative therapeutic value.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Afecto / Relación Dosis-Respuesta a Droga / Emociones / Alucinógenos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Afecto / Relación Dosis-Respuesta a Droga / Emociones / Alucinógenos Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido